Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

An IMiD-induced SALL4 degron system for selective degradation of target proteins

Open access
Yamanaka, Satoshi, Shoya, Yuki, Matsuoka, Saya, Nishida-Fukuda, Hisayo, Shibata, Norio, Sawasaki, Tatsuya · 2020 · Communications Biology

Abstract

Regulating the amount of proteins in living cells is a powerful approach for understanding the functions of the proteins. Immunomodulatory drugs (IMiDs) induce the degradation of neosubstrates by interacting with celebron (CRBN) in the cullin E3 ubiquitin ligase complex (CRL4 CRBN). Here, we developed the IMiD-dependent Sal-like protein 4 (SALL4) degron (S4D) system for chemical protein knockdown. In transient assays, an N- or C-terminal S4D tag induced the degradation of proteins localized to various subcellular compartments, including the plasma membrane. The activity of luciferase-S4D was reduced by 90% within 3 h of IMiD treatment. IMiD treatment reduced the expression of endogenous S4D-fused RelA and IκBα in knock-in (KI) experiments. Interestingly, the IκBα knockdown suggested that there may be another, unknown mechanism for RelA translocation to the nucleus. Furthermore, 5-hydroxythalidomide as a thalidomide metabolite specifically degradated S4D-tagged protein. These results indicate that the S4D system is a useful tool for cellular biology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-020-01240-5

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Construction of the IMiD-induced SALL4 degron (S4D) tag. a Amino acid sequence of IMiD-induced SALL4 degron. b Schematic diagram of the ORFs of the expression vector encoding Venus-SALL4 degron. c Immunoblot analysis of Venus-SALL4 degron protein. CRBN−/− HEK293T cells expressing AGIA-Venus-m1, -m2 (S4D), or -m3 and FLAG-CRBN were treated with DMSO (DM), thalidomide (Th), lenalidomide (Le), or pomalidomide (Po) for 16 h. d Immunoblot analysis of AGIA-Venus-S4D protein in CRBN−/− HEK293T cells expressing AGIA-S4D-WT and FLAG-CRBN treated with DM or Th in the presence of DM, MG132, or MLN4924 for 9 h. e Immunoblot analysis of Venus-S4D-WT or -G416A. CRBN−/− HEK293T cells expressing AGIA-Venus-S4D-WT or -G416A and FLAG-CRBN were treated with DM, Th, Le, or Po for 16 h. f Immunoblot analysis of Venus-S4D in HEK293T cells. HEK293T cells expressing AGIA-Venus-S4D were treated with DM, Th, Le, or Po for 16 h. g Schematic diagram of the ORF in an expression vector encoding FLuc and FLuc-S4D. h Immunoblot analysis of FLuc and FLuc-S4D. HEK293T cells expressing FLuc-AGIA or FLuc-S4D-AGIA were treated with DM, Th, Le, or Po for 16 h. i, j FLuc luciferase activity in lysates of HEK293T cells expressing FLuc-AGIA or FLuc-S4D-AGIA treated with DM, Th, Le, or Po for 16 h. k FLuc luciferase activity in lysates of HEK293T cells expressing FLuc-S4D-AGIA and treated with DMSO or 10 µM pomalidomide for the indicated times. l FLuc luciferase activity in lysates of HEK293T cells expressing FLuc-S4D-AGIA and treated with DM or Po in the presence of DM or MLN4924 for 12 h. Error bars in i-l represent the mean ± SD (n = 3).
Fig. 1 Construction of the IMiD-induced SALL4 degron (S4D) tag. a Amino acid sequence of IMiD-induced SALL4 degron. b Schematic diagram of the ORFs of the expression vector encoding Venus-SALL4 degron. c Immunoblot analysis of Venus-SALL4 degron protein. CRBN−/− HEK293T cells expressing AGIA-Venus-m1, -m2 (S4D), or -m3 and FLAG-CRBN were treated with DMSO (DM), thalidomide (Th), lenalidomide (Le), or pomalidomide (Po) for 16 h. d Immunoblot analysis of AGIA-Venus-S4D protein in CRBN−/− HEK293T cells expressing AGIA-S4D-WT and FLAG-CRBN treated with DM or Th in the presence of DM, MG132, or MLN4924 for 9 h. e Immunoblot analysis of Venus-S4D-WT or -G416A. CRBN−/− HEK293T cells expressing AGIA-Venus-S4D-WT or -G416A and FLAG-CRBN were treated with DM, Th, Le, or Po for 16 h. f Immunoblot analysis of Venus-S4D in HEK293T cells. HEK293T cells expressing AGIA-Venus-S4D were treated with DM, Th, Le, or Po for 16 h. g Schematic diagram of the ORF in an expression vector encoding FLuc and FLuc-S4D. h Immunoblot analysis of FLuc and FLuc-S4D. HEK293T cells expressing FLuc-AGIA or FLuc-S4D-AGIA were treated with DM, Th, Le, or Po for 16 h. i, j FLuc luciferase activity in lysates of HEK293T cells expressing FLuc-AGIA or FLuc-S4D-AGIA treated with DM, Th, Le, or Po for 16 h. k FLuc luciferase activity in lysates of HEK293T cells expressing FLuc-S4D-AGIA and treated with DMSO or 10 µM pomalidomide for the indicated times. l FLuc luciferase activity in lysates of HEK293T cells expressing FLuc-S4D-AGIA and treated with DM or Po in the presence of DM or MLN4924 for 12 h. Error bars in i-l represent the mean ± SD (n = 3).CC BY · PubMed Central
Fig. 2 IMiD treatment induced the degradation of proteins with various subcellular localizations. a Schematic diagram of the ORFs of the expression vectors encoding p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, and MAVS-S4D-AGIA. b Localization of transiently expressed proteins. Immunofluorescent staining of p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, or MAVS-S4D-AGIA in HeLa cells. Scale bars, 20 µm. c Immunoblot analysis of the dose-dependent degradation of proteins with various subcellular localizations. HeLa cells expressing p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, or MAVS-S4D-AGIA and FLAG-CRBN were treated with DMSO (DM) or pomalidomide (Po) for 16 h. d Immunoblot analysis of the indicated proteins in various subcellular localizations. CRBN−/− HEK293T cells expressing p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, or MAVS-S4D-AGIA and FLAG-CRBN were treated with DM or Po in the presence of DM or 2 µM MLN4924 for 9 h. e Immunoblot analysis of CRBN dependency on protein degradation of proteins with various subcellular localizations. Parental or CRBN−/− HEK293T cells expressing p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, or MAVS-S4D-AGIA were treated with DM or Po for 16 h. f Schematic diagram of the ORFs of the expression vectors encoding GM130-S4D-AGIA. g Localization of transiently expressed GM130. Immunofluorescent staining of GM130-S4D-AGIA in HeLa cells. Scale bars, 20 µm. h HeLa cells expressing GM130-S4D-AGIA were treated with DMSO (DM) or pomalidomide (Po) for 16 h. i Immunoblot analysis of CRBN dependency on protein degradation of GM130-S4D-AGIA. GM130-S4D-AGIA degradation was analyzed by same procedure in Fig. 2e. j, k Immunoblot analysis of N- or C-terminally tagged p53 (j) or DRD1 (k). HEK293T cells expressing S4D-p53-AGIA, p53-S4D-AGIA, S4D-DRD1-AGIA, or DRD1-S4D-AGIA were treated with DM, thalidomide (Th), or Po for 16 h.
Fig. 2 IMiD treatment induced the degradation of proteins with various subcellular localizations. a Schematic diagram of the ORFs of the expression vectors encoding p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, and MAVS-S4D-AGIA. b Localization of transiently expressed proteins. Immunofluorescent staining of p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, or MAVS-S4D-AGIA in HeLa cells. Scale bars, 20 µm. c Immunoblot analysis of the dose-dependent degradation of proteins with various subcellular localizations. HeLa cells expressing p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, or MAVS-S4D-AGIA and FLAG-CRBN were treated with DMSO (DM) or pomalidomide (Po) for 16 h. d Immunoblot analysis of the indicated proteins in various subcellular localizations. CRBN−/− HEK293T cells expressing p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, or MAVS-S4D-AGIA and FLAG-CRBN were treated with DM or Po in the presence of DM or 2 µM MLN4924 for 9 h. e Immunoblot analysis of CRBN dependency on protein degradation of proteins with various subcellular localizations. Parental or CRBN−/− HEK293T cells expressing p53-S4D-AGIA, STING-S4D-AGIA, DRD1-S4D-AGIA, or MAVS-S4D-AGIA were treated with DM or Po for 16 h. f Schematic diagram of the ORFs of the expression vectors encoding GM130-S4D-AGIA. g Localization of transiently expressed GM130. Immunofluorescent staining of GM130-S4D-AGIA in HeLa cells. Scale bars, 20 µm. h HeLa cells expressing GM130-S4D-AGIA were treated with DMSO (DM) or pomalidomide (Po) for 16 h. i Immunoblot analysis of CRBN dependency on protein degradation of GM130-S4D-AGIA. GM130-S4D-AGIA degradation was analyzed by same procedure in Fig. 2e. j, k Immunoblot analysis of N- or C-terminally tagged p53 (j) or DRD1 (k). HEK293T cells expressing S4D-p53-AGIA, p53-S4D-AGIA, S4D-DRD1-AGIA, or DRD1-S4D-AGIA were treated with DM, thalidomide (Th), or Po for 16 h.CC BY · PubMed Central
Fig. 3 Analysis using the S4D system in transient transfection assays. a Effect of pomalidomide-induced STING degradation on cGAMP-induced-ISRE luciferase reporter assay. HEK293T cells expressing STING-AGIA or STING-S4D-AGIA were treated with DMSO (DM) or pomalidomide (Po) for 16 h, and then stimulated with cGAMP for 3 h. b The expression of STING-AGIA or STING-S4D-AGIA in cells treated as described in Fig. 3a was analyzed by immunoblot. c Dose-dependent effects of cells treated as described in Fig. 3a. HEK293T cells expressing STING-S4D-AGIA were treated with DM, thalidomide (Th), or pomalidomide (Po) at the indicated concentration for 16 h, and then stimulated with cGAMP for 3 h. d Immunoblot analysis of phosphorylation of TBK1. HEK293T cells expressing STING-S4D-AGIA were treated with cGAMP for 3 h and analyzed by immunoblot. e Effect of pomalidomide-induced STING degradation on the phosphorylation of TBK1. HEK293T cells expressing STING-S4D-AGIA were treated with cGAMP for 3 h and analyzed by immunoblot. f Quantitative RT-PCR of cGAMP-induced genes. HEK293T cells expressing STING-S4D-AGIA were treated with DM or Po for 16 h, and then stimulated with cGAMP for 3 h. The expression of IFN-β, CXCL10, CCL5, and ISG56 was measured by quantitative RT-PCR. The mRNA expression in cells expressing an empty vector was set to 1.0. Error bars in a, c, and f represent the mean ± SD (n = 3 or 5), and P values were calculated by one-way ANOVA with Tukey’s post-hoc tests (NS not significant; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Fig. 3 Analysis using the S4D system in transient transfection assays. a Effect of pomalidomide-induced STING degradation on cGAMP-induced-ISRE luciferase reporter assay. HEK293T cells expressing STING-AGIA or STING-S4D-AGIA were treated with DMSO (DM) or pomalidomide (Po) for 16 h, and then stimulated with cGAMP for 3 h. b The expression of STING-AGIA or STING-S4D-AGIA in cells treated as described in Fig. 3a was analyzed by immunoblot. c Dose-dependent effects of cells treated as described in Fig. 3a. HEK293T cells expressing STING-S4D-AGIA were treated with DM, thalidomide (Th), or pomalidomide (Po) at the indicated concentration for 16 h, and then stimulated with cGAMP for 3 h. d Immunoblot analysis of phosphorylation of TBK1. HEK293T cells expressing STING-S4D-AGIA were treated with cGAMP for 3 h and analyzed by immunoblot. e Effect of pomalidomide-induced STING degradation on the phosphorylation of TBK1. HEK293T cells expressing STING-S4D-AGIA were treated with cGAMP for 3 h and analyzed by immunoblot. f Quantitative RT-PCR of cGAMP-induced genes. HEK293T cells expressing STING-S4D-AGIA were treated with DM or Po for 16 h, and then stimulated with cGAMP for 3 h. The expression of IFN-β, CXCL10, CCL5, and ISG56 was measured by quantitative RT-PCR. The mRNA expression in cells expressing an empty vector was set to 1.0. Error bars in a, c, and f represent the mean ± SD (n = 3 or 5), and P values were calculated by one-way ANOVA with Tukey’s post-hoc tests (NS not significant; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.CC BY · PubMed Central
Fig. 4 Generation and evaluation of knock-in (KI) cells expressing endogenous S4D-tagged protein. a Schematic diagram of S4D tag insertion at the C-terminus by genome editing using the CRISPR/Cas9 system. b Flowchart of the generation of sfGFP-S4D-tagged KI clones in HeLa cells. c Immunoblot analysis of S4D-tagged endogenous RelA and IκBα in KI cells. Parental, heterozygous, or homozygous KI cells were treated with DMSO (DM), 10 µM thalidomide (Th), or 10 µM pomalidomide (Po) for 24 h. d Immunoblot analysis of RelA-sfGFP-S4D and IκBα-sfGFP-S4D in each KI cell treated with DM or Po in the presence of DM, MG132, or MLN4924 for 9 h. e Dose-dependent degradation of S4D-tagged endogenous RelA and IκBα. Each KI cell was treated with DM, Th, or Po at the indicated concentration for 24 h, and the lysates were analyzed by immunoblot. f Time-dependent degradation of S4D-tagged endogenous RelA and IκBα. Each KI cell was treated with Po for the indicated times, and the lysates were analyzed by immunoblot. g Analysis of the reversibility of protein degradation in the S4D system by immunoblot. After each KI cell was treated with DM or Po for 6 h, the culture medium was replaced, and cells were harvested after the indicated times.
Fig. 4 Generation and evaluation of knock-in (KI) cells expressing endogenous S4D-tagged protein. a Schematic diagram of S4D tag insertion at the C-terminus by genome editing using the CRISPR/Cas9 system. b Flowchart of the generation of sfGFP-S4D-tagged KI clones in HeLa cells. c Immunoblot analysis of S4D-tagged endogenous RelA and IκBα in KI cells. Parental, heterozygous, or homozygous KI cells were treated with DMSO (DM), 10 µM thalidomide (Th), or 10 µM pomalidomide (Po) for 24 h. d Immunoblot analysis of RelA-sfGFP-S4D and IκBα-sfGFP-S4D in each KI cell treated with DM or Po in the presence of DM, MG132, or MLN4924 for 9 h. e Dose-dependent degradation of S4D-tagged endogenous RelA and IκBα. Each KI cell was treated with DM, Th, or Po at the indicated concentration for 24 h, and the lysates were analyzed by immunoblot. f Time-dependent degradation of S4D-tagged endogenous RelA and IκBα. Each KI cell was treated with Po for the indicated times, and the lysates were analyzed by immunoblot. g Analysis of the reversibility of protein degradation in the S4D system by immunoblot. After each KI cell was treated with DM or Po for 6 h, the culture medium was replaced, and cells were harvested after the indicated times.CC BY · PubMed Central
Fig. 5 Analysis of RelA-dependent signaling in RelA-sfGFP-S4D-KI cells. a Quantitative RT-PCR for the expression of TNF-α-induced genes. Parental or RelA-sfGFP-S4D-KI cells were pretreated with DMSO or pomalidomide (Po) for 24 h. Then, the cells were stimulated with 20 ng/ml TNF-α for 1 h, and the expression of IκBα or IL-6 was measured by quantitative RT-PCR. The mRNA expression in untreated parental HeLa cells was set to 1.0. b, c Pomalidomide causes TNF-α-induced cell death. Parental and RelA-sfGFP-S4D-KI cells pretreated with DMSO or Po for 12 h were stimulated with 20 ng/ml TNF-α for 12 h, and the viability was measured by MTS assay (b) or trypan blue staining (c). d Immunoblot analysis of pomalidomide-dependent TNF-α-induced cell death. Parental and RelA-sfGFP-S4D-KI cells pretreated with pomalidomide for 12 h were stimulated with 50 ng/ml TNF-α for the indicated times, and effectors of cell death were analyzed by immunoblot. e, f zVAD-FMK treatment rescued TNF-α-induced cell death in pomalidomide-treated KI cells. Parental and RelA-sfGFP-S4D-KI cells pretreated with 10 µM Po for 12 h were then treated with DMSO or 10 µM zVAD-FMK. After 2 h of zVAD-FMK treatment, the cells were stimulated with 50 ng/ml TNF-α for 12 h and the viability was measured by trypan blue staining (e), or effectors of apoptosis were analyzed by immunoblot (f). Error bars in a–c and e represent the mean ± SD (n = 3), and P values were calculated by one-way ANOVA with Tukey’s post-hoc tests (NS not significant; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Fig. 5 Analysis of RelA-dependent signaling in RelA-sfGFP-S4D-KI cells. a Quantitative RT-PCR for the expression of TNF-α-induced genes. Parental or RelA-sfGFP-S4D-KI cells were pretreated with DMSO or pomalidomide (Po) for 24 h. Then, the cells were stimulated with 20 ng/ml TNF-α for 1 h, and the expression of IκBα or IL-6 was measured by quantitative RT-PCR. The mRNA expression in untreated parental HeLa cells was set to 1.0. b, c Pomalidomide causes TNF-α-induced cell death. Parental and RelA-sfGFP-S4D-KI cells pretreated with DMSO or Po for 12 h were stimulated with 20 ng/ml TNF-α for 12 h, and the viability was measured by MTS assay (b) or trypan blue staining (c). d Immunoblot analysis of pomalidomide-dependent TNF-α-induced cell death. Parental and RelA-sfGFP-S4D-KI cells pretreated with pomalidomide for 12 h were stimulated with 50 ng/ml TNF-α for the indicated times, and effectors of cell death were analyzed by immunoblot. e, f zVAD-FMK treatment rescued TNF-α-induced cell death in pomalidomide-treated KI cells. Parental and RelA-sfGFP-S4D-KI cells pretreated with 10 µM Po for 12 h were then treated with DMSO or 10 µM zVAD-FMK. After 2 h of zVAD-FMK treatment, the cells were stimulated with 50 ng/ml TNF-α for 12 h and the viability was measured by trypan blue staining (e), or effectors of apoptosis were analyzed by immunoblot (f). Error bars in a–c and e represent the mean ± SD (n = 3), and P values were calculated by one-way ANOVA with Tukey’s post-hoc tests (NS not significant; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.CC BY · PubMed Central
Fig. 6 Analysis of IκBα-dependent signaling in IκBα-sfGFP-S4D-KI cells. a Nuclear and cytoplasmic fractions were obtained from parental and IκBα-sfGFP-S4D-KI (IκBα-KI) cells after treatment with 10 µM pomalidomide for the indicated times and were analyzed by immunoblot. b Parental and IκBα-sfGFP-S4D-KI (IκBα-KI) cells were pretreated with 10 µM pomalidomide for 24 h, and then stimulated with TNF-α for the indicated times. Nuclear and cytoplasmic fractions were analyzed by immunoblot.
Fig. 6 Analysis of IκBα-dependent signaling in IκBα-sfGFP-S4D-KI cells. a Nuclear and cytoplasmic fractions were obtained from parental and IκBα-sfGFP-S4D-KI (IκBα-KI) cells after treatment with 10 µM pomalidomide for the indicated times and were analyzed by immunoblot. b Parental and IκBα-sfGFP-S4D-KI (IκBα-KI) cells were pretreated with 10 µM pomalidomide for 24 h, and then stimulated with TNF-α for the indicated times. Nuclear and cytoplasmic fractions were analyzed by immunoblot.CC BY · PubMed Central
Fig. 7 5-Hydroxythalidomide treatment strongly degradates the S4D-tagged proteins but not degradates the I3D-tagged proteins. a Chemical structures of thalidomide (Th) and 5-hydroxythalidomide (5-HT). b Schematic diagram of the ORFs of S4D-FLuc-AGIA, FLuc-S4D-AGIA, and FLuc-I3D-AGIA in stable cell lines. c FLuc luciferase activity in lysates of HEK293T stable cells expressing S4D-FLuc-AGIA, FLuc-S4D-AGIA, or FLuc-I3D-AGIA treated with DMSO (DM), 1 µM thalidomide (Th), or 1 µM 5-hydroxythalidomide (5-HT) for 24 h. d, e Dose-dependent analyses of HEK293T stable cells expressing FLuc-S4D-AGIA or FLuc-I3D-AGIA treated with DM, Th, or 5-HT at the indicated concentration for 24 h. Luciferase activity analysis (d), immunoblot analysis (e), f Immunoblot analysis of RelA-sfGFP-S4D or IκBα-sfGFP-S4D in KI cells. Each KI cell was treated with DM, Th, 5-HT, or pomalidomide (Po) at the indicated concentration for 24 h. Error bars in c and d represent the mean ± SD (n = 3), and P values were calculated by one-way ANOVA with Tukey’s post-hoc tests (NS not significant; and ****P < 0.0001.
Fig. 7 5-Hydroxythalidomide treatment strongly degradates the S4D-tagged proteins but not degradates the I3D-tagged proteins. a Chemical structures of thalidomide (Th) and 5-hydroxythalidomide (5-HT). b Schematic diagram of the ORFs of S4D-FLuc-AGIA, FLuc-S4D-AGIA, and FLuc-I3D-AGIA in stable cell lines. c FLuc luciferase activity in lysates of HEK293T stable cells expressing S4D-FLuc-AGIA, FLuc-S4D-AGIA, or FLuc-I3D-AGIA treated with DMSO (DM), 1 µM thalidomide (Th), or 1 µM 5-hydroxythalidomide (5-HT) for 24 h. d, e Dose-dependent analyses of HEK293T stable cells expressing FLuc-S4D-AGIA or FLuc-I3D-AGIA treated with DM, Th, or 5-HT at the indicated concentration for 24 h. Luciferase activity analysis (d), immunoblot analysis (e), f Immunoblot analysis of RelA-sfGFP-S4D or IκBα-sfGFP-S4D in KI cells. Each KI cell was treated with DM, Th, 5-HT, or pomalidomide (Po) at the indicated concentration for 24 h. Error bars in c and d represent the mean ± SD (n = 3), and P values were calculated by one-way ANOVA with Tukey’s post-hoc tests (NS not significant; and ****P < 0.0001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 29

Metadata

Authors
Yamanaka, S., Shoya, Y., Matsuoka, S., Nishida-Fukuda, H., Shibata, N., & Sawasaki, T.
Affiliations
  • Ehime University (JP)
  • Nagoya Institute of Technology (JP)
Corresponding author
Sawasaki, Tatsuya
Venue
Communications Biology
Published
2020-09-18
Volume
3
Issue
1
Pages
515-515
ISSN
2399-3642 (ISSN-L)
OpenAlex
W3087018358
Cited by
29
References
52
Citations by year
2026: 2 · 2025: 5 · 2024: 7 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 1
FWCI
1.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Communications Biology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • MEXT | Japan Society for the Promotion of Science (JP17J08477, JP18K08574, JP17H06112, JP16H06579, JP16H04729, JP19H03218)
  • Japan Agency for Medical Research and Development (JP19am0101077)
  • Takeda Science Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
immunomodulators, cereblon, protein degradation, RelA, IκBα, NF-κB signaling, plasma membrane proteins
MeSH terms
Cell Membrane, HeLa Cells, Humans, Immunologic Factors, Substrate Specificity, Thalidomide, Transcription Factors, Transcriptional Elongation Factors, Ubiquitin-Protein Ligases, Transcription Factor RelA, Receptors, Interleukin-17, Gene Knockdown Techniques, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An IMiD-induced SALL4 degron system for selective degradation of target proteins. https://app.cochat.ai/papers/10.1038/s42003-020-01240-5
The paper
Yamanaka, S., Shoya, Y., Matsuoka, S., Nishida-Fukuda, H., Shibata, N., & Sawasaki, T. (2020). An IMiD-induced SALL4 degron system for selective degradation of target proteins. Communications Biology. https://doi.org/10.1038/s42003-020-01240-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.